Krystal Biotech (KRYS) Stock Forecast & Price Target

Krystal Biotech is attractive because Vyjuvek is already a commercially validated, first-in-class base business with broad labels, strong patient reimbursement, and expanding launches outside the US, supporting durable revenue growth toward a $1b topline model. The company’s economics are exceptional for biotech, with 2025 revenue of $389M, gross profit of $366M, about 94% gross margin, and $205M of net income, while 1Q26 cash of $1B and in-house manufacturing give it flexibility to fund pipeline expansion without heavy dilution. Beyond the core franchise, its HSV-1 platform is de-risked by an approved drug and offers multiple shots on goal in NK, ocular DEB, and CF, where positive early data and FDA discussions could unlock substantial upside.

Krystal Biotech is exposed to meaningful downside because valuation depends heavily on VYJUVEK, which contributes about 70% of the model, while pipeline assets add only modest support and therefore offer limited diversification. The company’s U.S. revenue has begun to plateau at roughly $88 million to $99 million since Q424, and more conservative expectations follow the 2Q26 earnings miss despite 730 reimbursements as of 2Q26. Fundamental risk also remains elevated across clinical execution, regulatory uncertainty, intellectual property, safety signals, and skepticism around the HSV-1 platform’s immunogenicity, redosing, and inhaled delivery feasibility.